Genome-wide association study of habitual physical activity in over 277,000 UK Biobank

participants identifies novel variants and genetic correlations with chronotype and obesity-related

traits.

Short Title: Genome-wide association study of habitual physical activity

Yann C. Klimentidis[1*], David A. Raichlen[2], Jennifer Bea[3,4], David O. Garcia[5], Lawrence J. Mandarino[6],

Gene E. Alexander[7], Zhao Chen[1], Scott B. Going[4]

[1] Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health,

University of Arizona, Tucson, Arizona, USA

[2] School of Anthropology, University of Arizona, Tucson, Arizona, USA

[3] Department of Medicine, University of Arizona, Tucson, Arizona, USA

[4] Department of Nutritional Sciences, University of Arizona, Tucson, Arizona, USA

[5] Department of Health Promotion Sciences, Mel and Enid Zuckerman College of Public Health,

University of Arizona, Tucson, Arizona, USA

[6] Center for Disparities in Diabetes, Obesity and Metabolism, Division of Endocrinology, Diabetes and

Metabolism, Department of Medicine, University of Arizona, Tucson, Arizona, USA

[7] Departments of Psychology and Psychiatry, Neuroscience and Physiological Sciences Interdisciplinary

Programs, BIO5 Institute, and Evelyn F. McKnight Brain Institute, University of Arizona, Tucson,

Arizona, USA; Arizona Alzheimer's Consortium, Phoenix, Arizona, USA

* Corresponding Author: Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman

College of Public Health, University of Arizona, Tucson, Arizona, 85724, 520-621-0147,

yann@email.arizona.edu

Abstract

Physical activity (PA) protects against a wide range of diseases. Engagement in habitual PA has been shown to be heritable, motivating the search for specific genetic variants that explain variation in habitual PA and may ultimately improve efforts to promote PA and target the best type of PA for each individual. We used data from the UK Biobank to perform the largest genome-wide association study of PA, using four measures based on self-report (n=277,656) and accelerometry (n=67,808). Replication was then sought in the Atherosclerosis Risk in Communities (ARIC) study (n=8,556). In the UK Biobank, we identified 17 genome-wide loci across the four PA measures. Interestingly, rs429358 of the *APOE* gene was the most strongly associated variant with any single PA measure and was at least nominally associated with three of the four PA measures examined. We also identified three loci (*DNAJC1*, *DCAF5*, and *PML*) consistently associated with PA across all four measures. Tissue enrichment analyses implicate the brain and pituitary gland as locations where PA-associated loci may exert their actions. Genetic correlation analyses suggest a positive genetic correlation of PA with early-morning chronotype and psychiatric traits, and a negative genetic correlation of PA with obesity-related traits. Using data from the GIANT consortium, we identify several loci that are associated with both increased waist circumference and decreased PA. Although very small effect sizes precluded replication of individual loci in ARIC, we found consistent overall genetic correlations of PA with other traits. These results provide new insight into the genetic basis of habitual PA, and the genetic links connecting PA and obesity.

Introduction

A physically active lifestyle has been shown to protect against a wide range of diseases, including cardiovascular disease, cancer, type-2 diabetes, and osteoporosis [1–4]. Levels of engagement in physical activity (PA) vary across individuals, and many people do not meet recommended levels to achieve health benefits. Although cultural, economic, and other environmental factors influence PA engagement [5,6], genetic factors also likely play a role. Understanding the genetic factors underlying inter-individual variation will better inform efforts to promote PA and potentially allow targeting the best type of PA for each person, what might be called "Precision Exercise Prescription".

Evidence of genetic factors underlying the propensity to exercise in humans has been demonstrated in a number of studies [7–14]. Several studies have utilized a candidate gene approach to identify specific genetic variants associated with a proclivity towards PA [8,15–19]. These studies generally focused on genes related to the serotonin and dopamine systems, energy metabolism, and neurotrophic factors. However, to our knowledge there have been only two previous reports of genome-wide association studies (GWAS) of PA [20,21], neither of which identified a locus at genome-wide significance, likely due to relatively small sample sizes. Thus, while previous work strongly suggests a genetic basis for engagement in PA, the genes that contribute strongly to this healthy lifestyle remain unknown.

In this study, we conduct the largest GWAS of PA to date, aiming to identify genetic variants associated with self-reported and accelerometry-based levels of habitual, leisure-time PA. We sought to identify variants in the UK Biobank, a large cohort study of 500,000 adults measured across a wide range of characteristics including genome-wide markers. We then examined the genetic correlation of PA with other traits, examined putative tissues where PA genes may exert their effects, and attempted to replicate our identified loci using self-reported PA in the Atherosclerosis Risk in Communities (ARIC) study.

Methods

Studies

Data from the UK Biobank study were used for discovery of variants. Briefly, the UK Biobank is a large prospective cohort study of approximately a half-million adults (ages 40-69) living in the United Kingdom (UK), recruited from 22 centers across the UK [22]. All participants provided written informed consent. For replication we used data from the ARIC study, which is a prospective cohort study of over 15,000 adults aged 45-64 years that took place in four United States communities. Details of the ARIC study can be found elsewhere [23]. To reduce the potential for confounding by population stratification, we included only individuals of white race/ethnicity in both studies.

Physical activity

In the UK Biobank, self-reported levels of physical activity during work and leisure time were measured via a touchscreen questionnaire, in a fashion similar to the International Physical Activity Questionnaire [24]. For moderate PA (MPA), participants were asked: "In a typical WEEK, on how many days did you do 10 minutes or more of moderate physical activities like carrying light loads, cycling at normal pace? (Do not include walking)". For vigorous PA (VPA), participants were asked: "In a typical WEEK, how many days did you do 10 minutes or more of vigorous physical activity? (These are activities that make you sweat or breathe hard such as fast cycling, aerobics, heavy lifting)". For each of these questions, those who indicated 1 or more such days were then asked "How many minutes did you usually spend doing moderate/vigorous activities on a typical DAY". Participants were asked to include activities performed for work, leisure, travel and around the house. We excluded individuals who selected "prefer not to answer" or "do not know" on the above questions, those reporting not being able to walk, and individuals reporting more than 16 hours of either MPA or VPA per day. Those reporting >3hr/day of VPA or MPA were recoded to 3 hours, as recommended [25]. Moderate-to-vigorous PA (MVPA) was

calculated by taking the sum of total minutes/week of MPA multiplied by four and the total number of

VPA minutes/week multiplied by eight, corresponding to their metabolic equivalents, as previously

described [24,26].

Since heritability has previously been shown to be higher for intense/vigorous physical activity

[13], we also considered VPA on its own. Because the distribution of minutes/week of VPA was highly

skewed and zero-inflated, we chose to dichotomize minutes/week of VPA into those who reported 0 days

of VPA, and those reporting 3 or more days of VPA and also reporting a typical duration of VPA that is

25 minutes or greater.

Also, in the UK Biobank, approximately 100,000 participants wore an Axivity AX3 wrist-worn

accelerometer, as previously described [27]. We examined two measures derived from up to seven days

of accelerometer wear: overall acceleration average, and fraction of accelerations > 425 milli-gravities

(mg) [27]. Since the variable that is available in the UK Biobank is the fraction < 425 mg, we subtracted 1

from this variable. The 425 mg cutoff was chosen because this corresponds to an equivalent of vigorous

physical activity, as previously reported [28]. For both accelerometry variables, we excluded individuals

with less than three days (72 hours) of data, those not having data in each one-hour period of the 24-hour

cycle, and outliers with values more than 4 standard deviations above the mean.

For the replication study (ARIC), self-reported PA was assessed for sports/exercise, within the

previous year, based on a modification of the Baecke questionnaire [29,30]. The sport/exercise index is

based on responses to 4 items: frequency of participation in sports/exercise; frequency of sweating during

sports/exercise; a subjective rating of the frequency of participation in sports/exercise compared to others

in the same age group; the sum of frequency, duration, and intensity of up to 4 sports/exercises.

Genotypes

The majority of UK Biobank participants were genotyped with the Affymetrix UK Biobank

Axiom Array (Santa Clara, CA, USA), while 10% of participants were genotyped with the Affymetrix

UK BiLEVE Axiom Array. Detailed quality control and imputation procedures are described elsewhere

[31]. Imputation was performed using a combined panel of the Haplotype Reference Consortium [32] and

the UK10K haplotype resource [33]. Since corrections for potential problems with the position

assignment of the SNPs from the UK10K haplotype resource were not available at the time of analysis,

we only included SNPs imputed from the Haplotype Reference Consortium. To minimize the possibility

of confounding due to population stratification, only participants who self-identified as White/British

(European-descent), and who were not population outliers based on principal components analysis (PCA)

were included. Individuals were excluded based on unusually high heterozygosity or >5% missing rate, a

mismatch between self-reported and genetically-inferred sex, and on relatedness (i.e. samples not used in

primary PCA). SNP exclusions were made based on Hardy-Weinberg equilibrium ($p<1\text{x}10^{-6}$), high

missingness (>1.5%), low minor allele frequency (<0.1%), and low imputation quality (info<0.4).

In ARIC, participants were genotyped with the Affymetrix Genome-Wide Human SNP Array 6.0

(Affymetrix, Santa Clara, CA, USA). Standard quality control procedures were implemented prior to

imputation with IMPUTE2 [34], using all individuals in the 1,000 Genomes phase 1 integrated v3 release.

Quality-control procedures consisted of excluding SNPs with minor allele frequency < 1%, with

missingness >10%, and SNPs out of Hardy-Weinberg equilibrium ($p<1 \text{ x } 10^{-6}$), and excluding individuals

with SNP missingness > 10%. We used principal components for the European-ancestry group as

provided by ARIC in dbGaP. Briefly, LD pruning resulted in 71,702 SNPs that were used to derive

principal components. A total sample size of 8,556 participants was used in the analysis.

Statistical analyses

For the continuous variables in the UK Biobank (MVPA and accelerometry variables) we created

an adjusted phenotype corresponding to the residual of the regression of the following independent

variables on the respective dependent PA variable: age, sex, genotyping chip, first ten genomic principal

components, center, season (month) at center visit or wearing accelerometer (coded 0 for Winter, 1 for

Fall or Spring, and 2 for Summer). In sensitivity analyses, we considered the inclusion of the additional

following covariates: levels of physical activity at work (coded as 0 by default, 1 for 'sometimes', 2 for

'usually', and 3 for 'always'), extent of walking or standing at work (coded similarly as previous

variable), and the Townsend Deprivation Index (TDI; a composite measure of deprivation as previously

described [35,36]). We also considered a third model in which body mass index (BMI) was included as an

additional covariate. Since the MVPA and fraction of accelerations > 425 mg variables exhibited skewed

distributions, we inverse-normalized these variables prior to inclusion in the models. Model residuals

conformed to the assumptions of normality and homoscedasticity. For the categorical variables, we used

logistic regression, including the same set of covariates listed above. We conducted two additional

analyses. First, we sought to identify variants consistently associated with PA across all four measures.

We thus searched for variants associated in the same direction, with $p<0.001$ with each of the four PA

phenotypes. The prior probability under the null hypothesis for a SNP association at this level with all

four phenotypes and with the same direction of association is $0.001 \times 0.0005 \times 0.0005 \times 0.0005 = 1.25 \times$

10^{-13}. However, it is important to note that these four phenotypes are correlated with each other. Second,

given the observed strong and consistent negative genetic correlation of all PA measures with waist

circumference we used summary statistics from the GIANT consortium [37] to identify loci that are

consistently associated with all four measures of PA in the same direction ($p<0.01$ in each of four PA

measures) and with waist circumference in the opposite direction ($p<0.01$).

Given the association that we identified with the rs428358 variant in *APOE*, we examined the

association of the *APOE* ε4 genotype, using this SNP along with the rs7412 SNP. Individuals with

homozygous CC genotypes at both of these SNPs were classified as homozygous for the APOE ε4 allele.

Individuals with homozygous CC genotypes at either SNP and heterozygous at the other SNP were

classified as being heterozygous for the ε4 allele. We excluded individuals heterozygous at both SNPs.

We assumed an additive model in association testing.

All genome-wide significant loci were examined in ARIC, where we modeled PA as a continuous

variable (as described above). We used multiple linear regression to model PA as a function of: age, sex,

first ten genomic principal components, BMI, center, season (coded in the same way as described above).

Residuals from this model conformed to the assumptions of normality and homoscedasticity, and were

used as the outcome in the genome-wide SNP association analysis. A replication was considered

successful if the p-value in ARIC was <0.0025, corresponding to a Bonferroni correction for 20 tests

performed. All GWAS analyses were performed with PLINK 2.0, assuming an additive genetic model

[38]. Additional analyses were performed with R statistical software[39]. To examine association of

genetic variants with gene expression patterns in different tissues, we used the web-based platform,

Functional Mapping and Annotation of Genome-Wide Association Studies (FUMA GWAS) [40], which

uses data from GTEx [41].

We used the summary statistics from our GWAS to examine genetic correlation of PA with over

200 traits and diseases using LD score regression [42,43], implemented in an online interface

(http://ldsc.broadinstitute.org/). The genetics of these other traits and diseases are inferred from

previously published GWAS. A significant genetic correlation was considered to have a $p < 2.5 \times 10^{-4}$,

assuming a correction for 200 different tests, which is conservative given that many of the traits/diseases

tested are correlated with each other. LD score regression intercepts and chip heritability estimates were

also recorded.

Results

Self-reported PA in UK Biobank

A summary of self-report PA variables can be found in Table 1. BMI and TDI were consistently

negatively associated with these variables, whereas season and physical activity at work were consistently

positively associated with them (see Supplementary Table 1). Self-report PA measures were weakly

correlated with accelerometry-based measures (see Supplementary Table 2). 'Chip heritability' estimates

for both self-report PA measures were approximately 5% (Supplementary Table 3). LD score regression

intercepts (<1.02) suggest no significant systematic inflation of test statistics. In over 277,000 individuals,

we find ten loci significantly associated ($p < 5 \times 10^{-8}$) with MVPA and three loci with VPA (see Figure 1

and Table 2). Most notably, the C allele at SNP rs429358 in *APOE* is associated with higher self-reported

MVPA. This allele is also nominally associated with higher levels of other measures of PA (VPA: p=8.4

$\times 10^{-6}$; average acceleration: $p=3.7 \times 10^{-3}$). Testing the association of the Alzheimer's disease-associated

APOE ε4 allele with MVPA resulted in nearly identical findings. In models adjusted for other covariates,

this *APOE* variant remained genome-wide significant (see Supplementary Tables 4 and 5). We did not

observe any loci significantly associated with both MVPA and VPA. In models adjusting for additional

covariates, the results were very similar with slightly fewer loci reaching genome-wide significance for

MVPA, and slightly more for VPA (see Supplementary Tables 4 and 5 and Supplementary Figures 1 and

2). In ARIC, we observed no significant replication of any variant. However, we note similar direction of

association for 8 of the 13 variants, including the *APOE* SNP (see Table 2).

Accelerometer-based PA in UK Biobank

'Chip heritability' estimates for the accelerometry-based measures were higher (15% for average

acceleration, and 11% for fraction of accelerations >425 mg) than for self-report PA measures

(Supplementary Table 3). LD score regression intercepts (<1.009) suggest no significant systematic

inflation of test statistics. Three loci were found to be significantly associated with average acceleration

and one locus with fraction of accelerations >425 mg (see Table 2 and Figure 1).

We found three loci associated with each of the four PA measures at p<0.001, and with the same

direction of association (Table 3). These include an intronic variant in *DNAJC1*, a variant just upstream of

DCAF5, and a missense variant in *PML*. No SNP was successfully replicated in ARIC.

Genetic correlation and tissue enrichment analysis

We examined the genetic correlation between habitual PA and over 200 hundred other

traits/diseases. Most notably, we find highly significant negative genetic correlations of PA with waist

and hip circumference, body fat, obesity, BMI, and triglycerides (see Figure 2). This negative genetic

correlation with obesity and related traits is particularly accentuated for the accelerometry-derived PA

variables (see Figure 2). We found three potentially pleiotropic loci associated with both lower physical

activity and greater waist circumference (see Table 4), including the *DNAJC1* variant previously

identified as being consistently associated with PA. We find a positive genetic correlation with

chronotype (morning-type) and psychiatric traits, and a negative genetic correlation of self-reported PA

with educational attainment traits. Results remained very similar in GWAS models adjusted for activity at

work and TDI variables (see Supplementary Figure 3), except that the negative correlation with

educational attainment traits exhibited a reversed direction of association. Similarly, upon addition of

BMI as a covariate, the direction of genetic correlation between PA and obesity traits was reversed (see

Supplementary Figure 4). As we note below, caution is warranted in interpreting results from these

adjusted models. In ARIC, we found similar genetic correlations of PA with waist circumference (r_g=-

0.13), chronotype (r_g=0.04), and schizophrenia (r_g=0.32), although these do not reach statistical

significance.

Tissue enrichment analysis using eQTL data from GTEx implicate the brain and pituitary as

primary tissues through which the PA-associated loci may exert their effects (see Figure 3 and

Supplementary Figure 5).

Discussion

Given the importance of physical activity for multiple dimensions of health, and its' reported

heritability, we sought to identify genetic variants that are associated with engagement in habitual

physical activity, while considering important covariates such as season, physical activity at work, socio-

economic status, and BMI.

In the UK Biobank, with a very large sample size and multiple measures of PA, we identified

several genome-wide significant SNPs. Interestingly, a well-established variant in *APOE* (part of *APOE*

ε4 allele)*,* strongly implicated in Alzheimer's disease [44,45], exhibited one of the strongest associations

with PA. How the *APOE* risk allele is associated with greater physical activity is not clear. An exercise

training study found that *APOE* ε4 carriers had a greater increase in aerobic capacity [46]. This increased

capacity could reinforce engagement in PA. Another potential explanation for our finding is that

individuals with a known family history of dementia or Alzheimer's disease purposefully increase their

levels of PA in order to avoid succumbing to these diseases. Nevertheless, it is important to note that this

association may lead to spurious gene-environment interactions [47]. This is particularly pertinent in the

case of the reported interactions of *APOE* with physical activity that suggest PA can have a beneficial

effect on Alzheimer's disease risk [e.g. 44–46]. Although this association remained after adjustment for

BMI and other covariates, it remains to be determined whether some residual confounding exists. None of

the identified loci were successfully replicated in the ARIC data, likely due to the very small effect sizes

observed in the UK Biobank, the smaller sample size in ARIC, and the different methods of measuring

physical activity in these studies. Additionally, it is important to note that none of the identified loci have

previously been found to be associated with PA or related traits [e.g. 16,17].

Previous studies have shown that BMI-associated genetic variants are also associated with PA

[51,52]. Similarly, we find an overall shared genetic basis for PA with several obesity-related traits,

suggesting that genetic risk for obesity coincides with genetic propensity for lower PA. There is likely a

complex set of genetic, environmental, and phenotypic factors that connect PA and obesity across the

lifespan, that involve many pleiotropic genetic factors. Although the direction of correlation is reversed

when BMI is included as a covariate, caution is warranted in interpreting results of genetic associations in

which heritable covariates are included in the association model [53]. Another major potential source of

bias is collider bias, which occurs when one controls for a variable (i.e. BMI) that is caused by both

another covariate (i.e. gene) and the outcome variable in the model (i.e. PA) [54,55].

Our study is strengthened by the large sample size, the availability of both self-reported and

accelerometer-based measures of PA, and the availability of a replication cohort from a different country.

However, we note several limitations. Given the relatively small genetic effect sizes observed for these

PA phenotypes, we were insufficiently powered to replicate associations in the much smaller sample size

in ARIC. Additional replication studies are thus needed to more robustly identify PA-associated loci.

Furthermore, the self-report measure of PA used in ARIC differed from the one used in the UK Biobank.

Both self-reported and accelerometer-based measures of PA are subject to various biases. Since both the

UK Biobank and ARIC cohorts are comprised of middle- to late-middle-aged adults, the extent to which

these results generalize to other age groups is not known. Furthermore, our results may not generalize to

other ethnic/racial groups.

In conclusion, our study revealed several important new findings. Effect sizes were generally

very small, given the very large sample size, variant allele frequencies, and modest p-values. *APOE*, a

major risk factor for Alzheimer's disease, is associated with higher levels of PA, which could importantly

lead to spurious *APOE*-by-PA interactions in epidemiological studies. We found a negative genetic

correlation of PA with obesity and related traits, suggesting extensive pleiotropy and complex

connections among PA and obesity. The identification of genetic factors that predispose to high or low

levels of physical activity will lead to a better understanding of the biological mechanisms underlying

these proclivities. It may also lead to the identification of individuals less likely to engage in and/or

adhere to physical activity, and consequently to the development of tailored behavioral strategies. Finally,

the integration of genetic information with lifestyle and environmental information may point to how

lifestyle/environmental factors interact with genetic factors to influence levels of PA.

Acknowledgments

This research was conducted using the UK Biobank Resource under Application Number 15678.

We thank the participants and organizers of the UK Biobank. We also thank the participants and

organizers of the ARIC study. Data from ARIC was obtained from dbGaP through accession number

phs000280.v2.p1. The authors would like to acknowledge support from the National Institute of Diabetes

and Digestive and Kidney Diseases grant (K01DK095032), the National Institute on Aging (AG019610),

the State of Arizona and Arizona Department of Health Services (ADHS), and the McKnight Brain

Research Foundation.

Atherosclerosis Risk in Communities

The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by

National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C,

HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C,

HHSN268201100011C, and HHSN268201100012C). Funding for GENEVA was provided by National

Human Genome Research Institute grant U01HG004402 (E. Boerwinkle). The authors thank the staff and

participants of the ARIC study for their important contributions.

LDHUB Acknowledgements

We gratefully acknowledge all the studies and databases that made GWAS summary data available:

ADIPOGen (Adiponectin genetics consortium), C4D (Coronary Artery Disease Genetics Consortium),

CARDIoGRAM (Coronary ARtery DIsease Genome wide Replication and Meta-analysis), CKDGen

(Chronic Kidney Disease Genetics consortium), dbGAP (database of Genotypes and Phenotypes),

DIAGRAM (DIAbetes Genetics Replication And Meta-analysis), ENIGMA (Enhancing Neuro Imaging

Genetics through Meta Analysis), EAGLE (EArly Genetics & Lifecourse Epidemiology Eczema

Consortium, excluding 23andMe), EGG (Early Growth Genetics Consortium), GABRIEL (A

Multidisciplinary Study to Identify the Genetic and Environmental Causes of Asthma in the European

Community), GCAN (Genetic Consortium for Anorexia Nervosa), GEFOS (GEnetic Factors for

OSteoporosis Consortium), GIANT (Genetic Investigation of ANthropometric Traits), GIS (Genetics of

Iron Status consortium), GLGC (Global Lipids Genetics Consortium), GPC (Genetics of Personality

Consortium), GUGC (Global Urate and Gout consortium), HaemGen (haemotological and platelet traits

genetics consortium), HRgene (Heart Rate consortium), IIBDGC (International Inflammatory Bowel

Disease Genetics Consortium), ILCCO (International Lung Cancer Consortium), IMSGC (International

Multiple Sclerosis Genetic Consortium), MAGIC (Meta-Analyses of Glucose and Insulin-related traits

Consortium), MESA (Multi-Ethnic Study of Atherosclerosis), PGC (Psychiatric Genomics Consortium),

Project MinE consortium, ReproGen (Reproductive Genetics Consortium), SSGAC (Social Science

Genetics Association Consortium) and TAG (Tobacco and Genetics Consortium), TRICL

(Transdisciplinary Research in Cancer of the Lung consortium), UK Biobank. We gratefully acknowledge

the contributions of Alkes Price (the systemic lupus erythematosus GWAS and primary biliary cirrhosis

GWAS) and Johannes Kettunen (lipids metabolites GWAS).

References

1.   Fiuza-Luces C, Garatachea N, Berger NA, Lucia A (2013) Exercise is the real polypill. Physiol.

2.   US Surgeon General (1996) Physical Activity and Health: A Report of the Surgeon General. S/N
017-023-00196-5.

3.   Blair SN (2009) Physical inactivity: the biggest public health problem of the 21st century. Br J
Sports Med 43: 1 LP-2.

4.   Kaplan GA, Strawbridge WJ, Cohen RD, Hungerford LR (1996) Natural history of leisure-time
physical activity and its correlates: associations with mortality from all causes and cardiovascular
disease over 28 years. Am J Epidemiol.

5.   Bauman AE, Reis RS, Sallis JF, Wells JC, Loos RJF, et al. (2012) Correlates of physical activity:
Why are some people physically active and others not? Lancet 380: 258–271.

6.   Trost SG, Owen N, Bauman AE, Sallis JF, Brown W (2002) Correlates of adults' participation in
physical activity: review and update. Med Sci Sport Exerc.

7.   den Hoed M, Brage S, Zhao JH, Westgate K, Nessa A, et al. (2013) Heritability of objectively
assessed daily physical activity and sedentary behavior. Am J Clin Nutr 98: 1317–1325.

8.   Gielen M, Westerterp-Plantenga MS, Bouwman FG, Joosen AMCP, Vlietinck R, et al. (2014)
Heritability and genetic etiology of habitual physical activity: a twin study with objective
measures. Genes Nutr 9: 415.

9.   Stubbe JH, Boomsma DI, Vink JM, Cornes BK, Martin NG, et al. (2006) Genetic influences on
exercise participation in 37.051 twin pairs from seven countries. PLoS One 1.

10.   Silventoinen K, Sammalisto S, Perola M, Boomsma DI, Cornes BK, et al. (2003) Heritability of
adult body height: a comparative study of twin cohorts in eight countries. Twin Res 6: 399–408.

11.   Joosen AMCP, Gielen M, Vlietinck R, Westerterp KR (2005) Genetic analysis of physical activity

in twins. Am J Clin Nutr 82: 1253–1259.

12.   Pérusse L, Tremblay A, Leblanc C, Bouchard C (1989) Genetic and environmental influences on

level of habitual physical activity and exercise participation. Am J Epidemiol.

13.   Lauderdale DS, Fabsitz R, Meyer JM, Sholinsky P, Ramakrishnan V, et al. (1997) Familial

determinants of moderate and intense physical activity: a twin study. Med Sci Sports Exerc 29:

1062–1068.

14.   Kaprio J, Koskenvuo M, Sarna S (1981) Cigarette smoking, use of alcohol, and leisure-time

physical activity among same-sexed adult male twins. Prog Clin Biol Res 69 Pt C: 37–46.

15.   Thompson PD, Tsongalis GJ, Ordovas JM, Seip RL, Bilbie C, et al. (2006) Angiotensin-

converting enzyme genotype and adherence to aerobic exercise training. Prev Cardiol.

16.   Herring MP, Sailors MH, Bray MS (2014) Genetic factors in exercise adoption, adherence and

obesity. Obes Rev 15: 29–39.

17.   Wilkinson A V., Gabriel KP, Wang J, Bondy ML, Dong Q, et al. (2013) Sensation-seeking genes

and physical activity in youth. Genes, Brain Behav.

18.   Caldwell Hooper AE, Bryan AD, Hagger MS (2014) What keeps a body moving? The brain-

derived neurotrophic factor val66met polymorphism and intrinsic motivation to exercise in

humans. J Behav Med 37: 1180–1192.

19.   Lightfoot JT (2011) Current understanding of the genetic basis for physical activity. J Nutr 141:

526–530.

20.   De Moor MHM, Liu Y-J, Boomsma DI, Li J, Hamilton JJ, et al. (2009) Genome-wide association

study of exercise behavior in Dutch and American adults. Med Sci Sports Exerc 41: 1887–1895.

21.   Kim J, Oh S, Min H, Kim Y, Park T (2011) Practical issues in genome-wide association studies

368   for physical activity. Ann N Y Acad Sci 1229: 38–44.

369   22.   Sudlow C, Gallacher J, Allen N, Beral V, Burton P, et al. (2015) UK Biobank: An Open Access

370   Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old

371   Age. PLoS Med 12.

372   23.   The Aric Investigators (1989) The Atherosclerosis Risk in Communities (ARIC) Study: design

373   and objectives. The ARIC investigators. Am J Epidemiol 129: 687–702.

374   24.   Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, et al. (2003) International physical

375   activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 35: 1381–1395.

376   25.   Ipaq, Sci M, Med S, Hardcastle S, Blake N, et al. (2002) Guidelines for Data Processing and

377   Analysis of the International Physical Activity Questionnaire (IPAQ) - Short Form. J Am Diet

378   Assoc.

379   26.   Ekelund U, Sepp H, Brage S, Becker W, Jakes R, et al. (2006) Criterion-related validity of the last

380   7-day, short form of the International Physical Activity Questionnaire in Swedish adults. Public

381   Health Nutr.

382   27.   Doherty A, Jackson D, Hammerla N, Plötz T, Olivier P, et al. (2017) Large Scale Population

383   Assessment of Physical Activity Using Wrist Worn Accelerometers: The UK Biobank Study.

384   PLoS One 12: e0169649.

385   28.   Hildebrand M, Van Hees VT, Hansen BH, Ekelund U (2014) Age group comparability of raw

386   accelerometer output from wrist-and hip-worn monitors. Med Sci Sports Exerc.

387   29.   Baecke JA, Burema J, Frijters JE (1982) A short questionnaire for the measurement of habitual

388   physical activity in epidemiological studies. Am J Clin Nutr 36: 936–942.

389   30.   Folsom AR, Arnett DK, Hutchinson RG, Liao F, Clegg LX, et al. (1997) Physical activity and

390   incidence of coronary heart disease in middle-aged women and men. Med Sci Sport Exerc 29:

391   901–909.

392   31.   Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, et al. (2017) Genome-wide genetic data on

393   ~500,000 UK Biobank participants. bioRxiv.

394   32.   McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, et al. (2016) A reference panel of

395   64,976 haplotypes for genotype imputation. Nat Genet.

396   33.   UK10K Consortium (2015) The UK10K project identifies rare variants in health and disease.

397   Nature.

398   34.   Howie B, Marchini J, Stephens M, Chakravarti A (2011) Genotype Imputation with Thousands of

399   Genomes. G3 GenesGenomesGenetics 1: 457–470.

400   35.   Townsend P (1987) Deprivation. J Soc Policy 16: 125–146.

401   36.   Smith GD, Whitley E, Dorling D, Gunnell D (2001) Area based measures of social and economic

402   circumstances: cause specific mortality patterns depend on the choice of index. J Epidemiol

403   Community Health.

404   37.   Shungin D, Winkler T, Croteau-Chonka D, Ferreira T, Mägi R, et al. (2015) New genetic loci link

405   adipose and insulin biology to body fat distribution. Nature 518: 187–196.

406   38.   Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, et al. (2015) Second-generation

407   PLINK: rising to the challenge of larger and richer datasets. Gigascience 4: 7.

408   39.   Team RDC (2011) R: A language and environment for statistical computing.

409   40.   Watanabe K, Taskesen E, van Bochoven A, Posthuma D (2017) FUMA: Functional mapping and

410   annotation of genetic associations. bioRxiv.

41. Consortium TGte (2015) The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene

regulation in humans. Sci 348: 648–660.

42. Zheng J, Erzurumluoglu AM, Elsworth BL, Kemp JP, Howe L, et al. (2017) LD Hub: a

centralized database and web interface to perform LD score regression that maximizes the

potential of summary level GWAS data for SNP heritability and genetic correlation analysis.

Bioinformatics 33: 272.

43. Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, et al. (2015) An Atlas of Genetic

Correlations across Human Diseases and Traits. bioRxiv.

44. Pericak-Vance MA, Bebout JL, Gaskell Jr. PC, Yamaoka LH, Hung WY, et al. (1991) Linkage

studies in familial Alzheimer disease: evidence for chromosome 19 linkage. AmJHumGenet.

45. Saunders AM, Strittmatter WJ, Schmechel D, St. George-Hyslop PH, Pericak-Vance MA, et al.

(1993) Association of apolipoprotein E allele ε4 with late-onset familial and sporadic alzheimer's

disease. Neurology.

46. Thompson PD, Tsongalis GJ, Seip RL, Bilbie C, Miles M, et al. (2004) Apolipoprotein e genotype

and changes in serum lipids and maximal oxygen uptake with exercise training. Metabolism 53:

193–202.

47. Dudbridge F, Fletcher O (2014) Gene-environment dependence creates spurious gene-

environment interaction. Am J Hum Genet 95: 301–307.

48. Smith JC, Nielson KA, Woodard JL, Seidenberg M, Durgerian S, et al. (2014) Physical activity

reduces hippocampal atrophy in elders at genetic risk for Alzheimer's disease. Front Aging

Neurosci 6.

49. Podewils L, Guallar E, Kuller L, Fried L, Lopez O, et al. (2005) Physical activity, APOE

genotype, and dementia risk: findings from the cardiovascular health cognition study. Am J

Epidemiol 161.

50.   Rovio S, Kåreholt I, Helkala E-L, Viitanen M, Winblad B, et al. (2005) Leisure-time physical

activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol 4: 705–711.

51.   Lee H, Ash GI, Angelopoulos TJ, Gordon PM, Moyna NM, et al. (2015) Obesity-Related Genetic

Variants and their Associations with Physical Activity. Sport Med Open 1: 34.

52.   Richmond RC, Davey Smith G, Ness AR, den Hoed M, McMahon G, et al. (2014) Assessing

Causality in the Association between Child Adiposity and Physical Activity Levels: A Mendelian

Randomization Analysis. PLoS Med 11.

53.   Aschard H, Vilhjalmsson BJ, Joshi AD, Price AL, Kraft P (2015) Adjusting for heritable

covariates can bias effect estimates in genome-wide association studies. Am J Hum Genet 96:

329–339.

54.   Day FR, Loh P-R, Scott RA, Ong KK, Perry JR (2016) A Robust Example of Collider Bias in a

Genetic Association Study. Am J Hum Genet 98: 392–393.

55.   Yaghootkar H, Bancks MP, Jones SE, McDaid A, Beaumont R, et al. (2017) Quantifying the

extent to which index event biases influence large genetic association studies. Hum Mol Genet 26:

1018–1030.

Figure Legends

Figure 1: Manhattan plot of GWAS for self-reported MVPA and VPA and for accelerometer-based average accelerations and fraction of accelerations > 425 mg. Negative log10-transformed p-value for each SNP is plotted by chromosome and position (x-axis). The red and blue horizontal lines represent thresholds for genome-wide significant and suggestive associations, respectively.

Figure 2: Genetic correlation of PA variables with other traits and diseases. Traits/diseases are ordered from top to bottom in order of increasing p-value for the ten traits/diseases with strongest degree (according to p-value) of genetic correlation with respective measure of PA. Horizontal position of bars corresponds to the genetic correlation (r_g) between PA and the respective trait/disease. Error bars represent 95% confidence intervals for r_g estimates. Bright green bars represent traits that showed a correlation with p-value <2.5E-4, and light green bars represent traits with genetic correlation p<0.05. We excluded highly redundant traits (e.g. obesity, overweight) after leaving higher ranked one in.

Figure 3: Results of tissue enrichment analysis using eQTL results from GTEx RNA-seq data for PA-associated loci.

468 **Table 1: Summary of PA phenotypes in the UK Biobank**

Self-Report	
MVPA	Mean=1,646; SD=2,075; n=277,656
Vigorous PA: 0 vs. ≥3 days/week	71,739 cases; 119,866 controls
Accelerometry	
Average acceleration (milli-gravities)	Mean=27.93; SD=8.15; n=67,808
Fraction accelerations > 425 milli-gravities	Mean=0.0026 ; SD=0.0033 ; n=67,565

469 SD: standard deviation

472 **Table 2:** Summary of polymorphisms identified in the UK Biobank with association statistics in ARIC.

SNP ID	Chr.	Gene/Nearest Gene	Position	EA	EAF	Beta/OR	p-value	n	ARIC replication Beta	ARIC replication p-value
MVPA										
rs429358	19	*APOE*	45,411,941	T	0.84	-0.023	4.98E-11	277,656	-0.026	0.260
rs72737787	9	ZCCHC7	37,336,741	G	0.65	-0.017	3.66E-10	277,656	-0.026	0.049
rs1043595	7	*CALU*	128,410,012	G	0.72	0.017	1.48E-09	277,656	0.014	0.310
rs1921981	21	BACE2	42,422,547	G	0.67	0.016	4.03E-09	277,656	0.021	0.106
rs3129981	6	HCG20	30,758,857	C	0.83	0.020	5.13E-09	277,656	0.007	0.730
rs921917	7	*C7orf72*	50,228,738	C	0.51	-0.015	1.19E-08	277,656	-0.007	0.568
rs12147808	14	*C14orf64*	98,618,705	C	0.79	-0.018	1.30E-08	277,656	-0.009	0.484
rs124672	8	KCNK9	140,722,178	A	0.71	-0.016	2.22E-08	277,656	0.003	0.840
rs148854222	5	*SLC1A3*	36,505,944	T	0.997	-0.137	2.87E-08	277,656	0.066	0.645
rs12142550	1	*HAX1*	154,258,549	C	0.75	0.016	4.60E-08	277,656	-0.011	0.461
Vigorous PA: 0 vs. ≥3 days/week										
rs6955240	7	*EXOC4*	133,581,873	G	0.61	1.044	9.57E-10	191,473	0.001	0.905
rs6667222	1	*HAX1*	154,253,661	A	0.75	1.046	9.55E-09	191,473	-0.014	0.340
rs6909774	6	*MMS22L*	97,687,471	A	0.25	1.044	3.34E-08	191,473	-0.035	0.014
Accelerometry – Average acceleration										
rs62055545	17	*MAPT-AS1*	43,964,561	C	0.78	-0.038	1.41E-09	67,808	0.006	0.680
rs34517439	1	*FUBP1*	78,450,517	C	0.88	0.044	4.23E-08	67,808	-0.010	0.635
rs4747438	10	*DNAJC1*	22,124,263	C	0.32	-0.030	4.62E-08	67,808	0.009	0.485
Accelerometry – Fraction accelerations > 425 milli-gravities										
rs10851869	15	*PML*	74,331,083	T	0.57	0.027	3.66E-08	67,565	0.015	0.227

473   EA refers to effect allele that Beta/OR corresponds to. EAF: effect allele frequency; proxy rs2732705 SNP was used
474   for rs62055545 in ARIC
475

476   **Table 3:** Loci consistently associated with PA across all four measures (each p<0.001).

SNP	Chr.	Nearest Gene	Position	Effect Allele	MVPA		VPA		AA		AF>425		ARIC PA	
					Beta	p	OR	p	Beta	p	Beta	p	Beta	p
rs7910002	10	*DNAJC1*	22050570	G	-0.01	8.7E-04	0.97	2.8E-04	-0.03	7.9E-08	-0.02	1.0E-04	0.005	0.716
rs10135643	14	*DCAF5*	69517406	A	0.01	6.5E-04	1.03	1.7E-04	0.02	4.6E-04	0.02	2.2E-04	0.023	0.064
rs5742915	15	*PML*	74336633	T	-0.01	3.7E-06	0.96	1.3E-07	-0.02	2.4E-05	-0.02	3.0E-06	0.002	0.873

477   AA: Average acceleration, AF>425: acceleration fraction greater than 425mg, ARIC PA: Physical

478   activity in ARIC study.

480   **Table 4:** Loci consistently associated with all four PA variables and with waist circumference from
481   GIANT consortium (each p<0.01)
482

SNP	Chr	Nearest Gene	Position	Effect Allele	MVPA		VPA		AA		AF>425		Waist circum.	
					Beta	p	OR	p	Beta	p	Beta	p	Beta	p
rs12993490	2	*CPS1, ERBB4*	211,953,629	C	0.01	4.1E-03	1.03	3.1E-04	0.02	4.4E-04	0.01	9.1E-03	-0.016	1.1E-03
rs7910002	10	*DNAJC1*	22,050,570	G	-0.01	8.7E-04	0.97	2.8E-04	-0.03	7.9E-08	-0.02	1.0E-04	0.015	7.5E-04
rs7250389	19	*CCNE1*	30,325,332	G	0.01	2.4E-03	1.03	1.7E-04	0.03	3.7E-06	0.02	3.5E-05	-0.02	2.1E-05

483   AA: Average acceleration, AF>425: acceleration fraction greater than 425mg

484
485

486   **Figure 1**

MVPA

VPA 3-plus vs. 0 days

Average Acceleration

Fraction of Accelerations > 425 mg

488 **Figure 2**

490   **Figure 3**